Rheumnow Podcast

Do we need more IL-17 and JAK Inhibitors in Spondyloarthritis?

Dr. Eric Ruderman shares his perspectives on the following abstracts being presented at Eular 2024 in Vienna, Austria:

OP0195 Sonelokimab IL 17 A/F nanobody inhibitor
LB0005 Izokibep IL17A nanobody inhibitor
POS0803 Vunakizumab, another IL17A inhibitor
OP0138 TAK-279 phase 2B selective TYK2 inhibitor Zasocitinib

Voclosporin and Steroids in Lupus Nephritis

Dr. Jack Cush reports on abstract OP0059 presented at Eular 2024 in Vienna, Austria.

 

3 Big Lupus Themes from EULAR 2024

Dr. Janet Pope discusses three hot topics in lupus at Eular 2024 in Vienna, Austria. 

Does B Cell Depletion Matter?

Drs. Yuz Yusof and Ed Vital discuss abstract OP0077 at Eular 2024 in Vienna, Austria.

Do MRI changes at the Spine and SI Joints in Treatment of AxSpA Matter?

Dr. Eric Ruderman discusses abstracts OP0046 and POS0058 presented at Eular 2024 in Vienna, Austria.

OP0046 Effect on SI joint structural lesions with ixekizumab
POS0058 Effect on SI joint structural lesions with bimekizumab

Do we need more IL-17 and JAK Inhibitors in Spondyloarthritis?

Dr. Eric Ruderman shares his perspectives on the following abstracts being presented at Eular 2024 in Vienna, Austria:

OP0195 Sonelokimab IL 17 A/F nanobody inhibitor
LB0005 Izokibep IL17A nanobody inhibitor
POS0803 Vunakizumab, another IL17A inhibitor
OP0138 TAK-279 phase 2B selective TYK2 inhibitor Zasocitinib

Do we need more IL-17 and JAK Inhibitors in Spondyloarthritis?

Dr. Eric Ruderman shares his perspectives on the following abstracts being presented at Eular 2024 in Vienna, Austria:

OP0195 Sonelokimab IL 17 A/F nanobody inhibitor
LB0005 Izokibep IL17A nanobody inhibitor
POS0803 Vunakizumab, another IL17A inhibitor
OP0138 TAK-279 phase 2B selective TYK2 inhibitor Zasocitinib

Is Cannabis Safe? (6.7.2024)

Dr. Jack Cush reviews FDA approval, news and journal articles -- Its the week before EULAR 2024 in Vienna!!

ACR’s Run at Goliath (PCPs) (5.31.2024)

Dr. Jack Cush reviews the journal reports and articles from this past week on RheumNow.com.  The ACR (and Cush) address their new website designed to educate PCPs and APP's - what do you think?

The Window of Opportunity (5.24.2024)

Dr. Jack Cush reviews the journal reports and news from the past week on RheumNow.com. This week blockbuster drugs, opioids in rheumatology and nontreatment of inflammatory arthritis?